ACET Stock Overview
A clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Adicet Bio, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.51 |
52 Week High | US$3.77 |
52 Week Low | US$1.05 |
Beta | 1.69 |
11 Month Change | 16.15% |
3 Month Change | 7.86% |
1 Year Change | -16.57% |
33 Year Change | -81.03% |
5 Year Change | n/a |
Change since IPO | -90.19% |
Recent News & Updates
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
Jul 12Adicet Bio: Microcap With A High Risk To Reward Ratio
May 23Recent updates
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
Jul 12Adicet Bio: Microcap With A High Risk To Reward Ratio
May 23Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate
Feb 01Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?
Dec 07Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?
Aug 07Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Apr 20Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation
Dec 20Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio
Oct 17Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?
Oct 04Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term
Aug 16Adicet Bio: A First Take
Jul 22Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Jul 07Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit
May 15We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
Mar 18Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate
Feb 09Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management
Dec 28Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Dec 16Shareholder Returns
ACET | US Biotechs | US Market | |
---|---|---|---|
7D | 3.4% | -1.7% | -1.4% |
1Y | -16.6% | 13.9% | 21.1% |
Return vs Industry: ACET underperformed the US Biotechs industry which returned 13.4% over the past year.
Return vs Market: ACET underperformed the US Market which returned 20.9% over the past year.
Price Volatility
ACET volatility | |
---|---|
ACET Average Weekly Movement | 10.5% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACET's share price has been volatile over the past 3 months.
Volatility Over Time: ACET's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 143 | Chen Schor | www.adicetbio.com |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Adicet Bio, Inc. Fundamentals Summary
ACET fundamental statistics | |
---|---|
Market cap | US$122.78m |
Earnings (TTM) | -US$137.29m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs ACET overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ACET income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$137.29m |
Earnings | -US$137.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.67 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ACET perform over the long term?
See historical performance and comparison